Posted by Michael Wonder on 20 Oct 2021
Chiesi Global Rare Diseases announces approval of Ferriprox (deferiprone) in Canada for the treatment of iron overload in sickle cell disease
15 October 2021 - Chiesi Global Rare Diseases announced today that Health Canada has approved Ferriprox (deferiprone) for the treatment of iron overload in patients with sickle cell disease or other anemias.
Ferriprox was previously approved in Canada for the treatment of iron overload in patients with thalassemia major when current chelation therapy is inadequate.
